Abstract: Propofol is widely used for neurosurgical anesthesia; however, its effects on the pial microvasculature are unknown. We therefore evaluated the direct effects of propofol on pial microvessels in rabbits. Pial microcirculation was visualized using a closed cranial window technique in 20 Japanese white rabbits. In the first experiment (n = 14), after baseline hemodynamic measurements, the cranial window was superfused with 5 increasing concentrations of propofol (10
Abstract: Propofol is widely used for neurosurgical anesthesia; however, its effects on the pial microvasculature are unknown. We therefore evaluated the direct effects of propofol on pial microvessels in rabbits. Pial microcirculation was visualized using a closed cranial window technique in 20 Japanese white rabbits. In the first experiment (n = 14), after baseline hemodynamic measurements, the cranial window was superfused with 5 increasing concentrations of propofol (10 À 8 , 10
À 7 , 10 À 6 , 10
À 4 mol/L; n = 8) or intralipid (at comparable concentrations; n = 6) dissolved in artificial cerebrospinal fluid for 7 minutes each. A typical anesthetic concentration of 5 mg/mL corresponds to 10 À 6 mol/L. In the second experiment (n = 6), phenylephrine 10 À 6 mol/L and nitroglycerin 10 À 6 mol/L were applied topically for 7 minutes under pentobarbital anesthesia. In the third experiment (n = 3), electroencephalogram and bispectral index were measured under pentobarbital anesthesia. Diameters of selected pial arterioles and venules were visualized with a microscope-video capture unit combination and subsequently measured with a digital video analyzer. Topical application of propofol at 10 À 8 , 10
, 10 À 6 , or 10 À 5 mol/L did not alter the diameters of the pial microvessels; however, at 10 À 4 mol/L propofol induced dilation in large and small arterioles, along with venular dilation. Intralipid alone did not have any significant effect on vessel diameters. Phenylephrine and nitroglycerin produced pial arteriolar and venular constriction and dilation, respectively. Phenylephrine constricted and nitroglycerin dilated pial arterioles and venules. Pentobarbital did not produce either burst suppression or an isoelectric electro- C oncentrations of volatile anesthetics that might be used in routine cases are at least relatively contraindicated in neurosurgical patients with increased intracranial pressure because most of them except sevoflurane 1 increase cerebral blood flow (CBF) 2 and suppress motorevoked potentials. 3 In contrast, propofol better maintains motor-evoked potentials 4 and reduces CBF. 5 Furthermore, several studies suggest that propofol provides a degree of neuroprotection. 6, 7 Propofol thus seems to be useful for neuroanesthesia and is commonly used for this purpose.
Normally, changes in CBF are associated with wellmatched and proportional changes in cerebral metabolic rate (CMR).
2 Dexmedetomidine-a potent cerebral vasoconstrictor 8 -decreases CBF more than CMR, 9 though recent work from Drummond et al 10 reported that dexmedetomidine produced similar decreases in CBF and CMR. Propofol also decreases CBF more than CMR, 11 suggesting that propofol has a cerebrovascular constrictor property. In contrast, propofol is known to produce systemic vascular dilation. 12, 13 Why cerebral and systemic vessels should respond so differently to propofol, and even whether they do, remains unclear.
There are a few reports concerning the effects of propofol on cerebral vessels in vitro, [14] [15] [16] however, none reports the reactivity of cerebral vessels to propofol in vivo. We therefore evaluated the in vivo effects of propofol on pial microvessels in rabbits using the cranial window technique. Specifically, we tested the hypothesis that clinically relevant concentrations of propofol do not dilate pial arterioles or venules. rabbits weighing 2.8 to 3.9 kg. After obtaining intravenous (IV) access in an ear vein, the animals were anesthetized with pentobarbital sodium (20 mg/kg IV) and ketamine (2 mg/kg IV). Anesthesia was maintained with an infusion of pentobarbital sodium (5 mg/kg/h). The animals' core body temperature was maintained at 39 ± 0.51C using a heating blanket. The animals were tracheostomized and their lungs mechanically ventilated with an oxygen-air mixture. End-tidal CO 2 5 mEq/L) was infused at 10 mL/kg/h. A closed cranial window was used to visualize the pial microcirculation. Each rabbit was placed in the sphinx posture. The scalp was retracted and a 0.8 cm diameter hole was made in the parietal bone. After bipolar coagulation of dural vessels, the dura and arachnoid membranes were cut and a thin ring of glass was positioned over the hole and secured with bone wax and dental acrylic. The space under the window was filled with artificial cerebrospinal fluid (aCSF), and 3 polyethylene catheters were inserted into the ring. One catheter was attached to a reservoir bottle containing aCSF, which was continuously bubbled with 5% CO 2 in air. The aCSF was suffused at 0.1 mL/min. Two other catheters served as an inlet and an outlet for aCSF and study drug solutions. The level of the outlet was maintained approximately 5 to 6 cm above the window to maintain normal intracranial pressure. The volume of fluid below the window was between 0.5 and 0.7 mL. The composition of aCSF was Na + 151 mEq/L, K
25 mEq/L, urea 40 mg/dL, and glucose 65 mg/dL. Before starting each experiment, responsiveness of the pial vessels was tested by altering the respiratory rate to increase or decrease ETCO 2 by 10 mm Hg and confirming a 5% to 10% diameter change.
In the first experiment (n = 14), propofol (Diprivan, AstraZeneca, Osaka, Japan) was freshly dissolved in aCSF to obtain concentrations of 10 À 8 , 10 À 7 , 10 À 6 , 10 À 5 , and 10 À 4 mol/L solutions (Propofol group). Intralipid (Terumo, Tokyo, Japan) with disodium edetate 55 mg, which is similar to the vehicle for propofol, was also dissolved in aCSF at analogous concentrations (Intralipid group). After a 30-minute stabilization period, control values for pial arteriolar and venular diameters and various laboratory data including MAP, heart rate (HR), rectal temperature, arterial blood gas tensions and pH, plasma electrolytes, and glucose concentration were recorded. The cranial window was then superfused with either propofol (n = 8) or intralipid (n = 6) in escalating concentrations. Superfusion rate was initially set at 0.5 mL/min for 2 minutes. Because space under the window was approximately 0.5 mL, superfusion rate at 0.5 mL/min for 2 minutes was sufficient to clear aCSF in the window. Subsequently, infusion rate was decreased to 0.1 mL/min for 5 minutes. This ensured a steady-state superfusion. We measured the diameters of pial vessels, MAP, HR, and rectal temperature once, 7 minutes after application of each propofol or intralipid concentration. The window was then flushed with aCSF for 40 minutes before the next concentration was administered. aCSF and all solutions were warmed to 39.01C in a water bath.
In the second experiments with 6 rabbits, we examined the effects of phenylephrine and nitroglycerin on pial arterioles and venules under pentobarbital anesthesia. Phenylephrine and nitroglycerin were dissolved in aCSF to make a 10 À 6 mol/L solution. In 3 rabbits, we topically superfused phenylephrine, nitroglycerin, phenylephrine, and nitroglycerin in turns. In the other 3 rabbits, we topically superfused nitroglycerin, phenylephrine, nitroglycerin, and phenylephrine. Superfusion method was the same as the first experiments.
In the third experiments with 3 rabbits, we observed the electroencephalogram (EEG) and bispectral index (BIS) under pentobarbital anesthesia. Cranial window was not implanted. The 4-electrode sensor was applied to monitor the EEG and the BIS. One electrode was placed 1 cm caudal to the eyehole and others were placed on the head. All electrode impedance levels were kept below 7.5 kO. The EEG and the BIS value were obtained from an A-2000 monitor (Version XP-3.12, Aspect Medical Systems, Norwood, MA). The BIS smoothing rate was set at 15 seconds. Monitoring duration was comparable to the first experimental period.
The diameters of 4 pial arterioles and 3 or 4 venules were measured in each cranial window using a digital video analyzer (VH Analyzer VH-H1A5, Keyence, Osaka, Japan) on a personal computer that was attached to a microscope (VH-5000, Keyence, Osaka, Japan) via video capture unit (VH-E500, Keyence, Osaka, Japan). Data from the pial views were stored on the computer hard disk for subsequent analysis after the experiments. Measurements of pial arteriolar and venular diameters were performed by an investigator who did not participate in the experimental procedures.
Propofol inhibits sympathetic vasoconstrictor nerve activity, 17 and the sympathetic contractile response to norepinephrine is substantial in first-order vessel branches but relatively less in second-order vessel branches in the rabbit middle cerebral tree. 18 Mean diameter of second branch is 67 mm. 19 Sizes of the measured blood vessels were thus divided on the basis of initial diameters into 2 subgroups: >70 (large) and r70 (small) micrometers.
Mean arterial pressure, HR, body temperature, arterial blood pH, PaCO 2 , PaO 2 , and plasma concentrations of Na + , K + , and glucose in each experimental group were compared using 1-way analysis of variance (ANOVA) and post hoc Fisher protected least significant difference tests. Concentration-dependent effects of propofol and intralipid were examined via ANOVA and Fisher protected least significant difference test for post hoc comparisons. Effects of phenylephrine and nitroglycerin on pial vessels were analyzed using ANOVA for repeated measurements, followed by the Dunnett post hoc test. Values are represented as means ± SDs; P value less than 0.05 was considered statistically significant.
RESULTS
Body weight of the eight rabbits in the Propofol group was 3.6 ± 0.4 kg; it was 3.5 ± 0.2 kg in the six animals of the Intralipid group (P = 0.41). MAP, HR, rectal temperature, arterial pH, PaCO 2 , PaO 2 , and plasma Na + , K + and glucose concentrations did not change significantly in either group during the experimental period (Tables 1, 2 ). Furthermore, MAP and HR were not affected by topical application of either propofol, intralipid, phenylephrine, or nitroglycerin.
Predrug diameters of large arterioles (100 to 105 mm), small arterioles (50 to 54 mm), large venules (114 to 117 mm), and small venules (49 to 53 mm) did not differ significantly in either group, or among the tested doses. Propofol at 10 À 8 to 10 À 5 mol/L did not produce any significant change in pial arterioles (Fig. 1A) and venules (Fig. 1B) . Propofol at 10 À 4 mol/L induced slight dilation of large pial arterioles (n = 16, predrug 102 ± 19 mm vs. postdrug 108 ± 19 mm, P<0.05) and small pial arterioles (n = 16, predrug 52 ± 11 mm vs. postdrug 57 ± 12 mm, P<0.05). Propofol at 10 À 4 mol/L also induced slight dilation of large venules (n = 15, predrug 116 ± 44 mm vs. postdrug 122 ± 45 mm, P<0.05) and small venules (n = 14, predrug 51 ± 12 mm vs. postdrug 54 ± 11 mm, P<0.05). In contrast, intralipid did not affect the diameters of pial vessels at any of the concentrations tested (Figs. 1A, B) .
Phenylephrine produced a significant constriction on pial arterioles and venules (Figs. 2A, B) . Nitroglycerin produced a significant dilation on pial arterioles and venules (Figs. 2A, B) . Pial arterioles and venules always responded to topical application of phenylephrine or nitroglycerin (Figs. 2A, B) . After 40 minutes of stabilization, pial arteriolar and venular diameters returned to control values (Figs. 2A, B) .
Pentobarbital anesthesia did not produce either burst suppression or an isoelectric EEG (Fig. 3) . BIS was stable and showed between 64 and 82 throughout the study period (Fig. 3) . Data are expressed as mean ± SD. There was no difference among each application period. BS indicates blood glucose concentration; End, at the end of experiment; HR, heart rate; MAP, mean arterial blood pressure; N, nitroglycerin; P, phenylephrine; RT, rectal temperature.
DISCUSSION
The direct in vivo effect of propofol on cerebral vessels has not been evaluated previously. On the other hand, the relationship between propofol and CBF is well established. 2 Whereas changes in CBF are normally associated with a proportional change in CMR, dexmedetomidine and propofol both reduce CBF more than CMR. 2 This combination suggests that both drugs are cerebrovascular constrictors.
Our results, though, suggest that propofol at 10
to 10 À 5 mol/L has no effect on pial microvascular diameters. Only the highest concentration of propofol (10 À 4 mol/L) dilated pial arterioles and venules, and then only slightly. Intralipid, which is similar to the vehicle for propofol, did not alter the size of the pial microvessels at any tested concentration, indicating that what little dilation was observed did not result from the vehicle. Our results are consistent with previous in vitro studies showing that propofol did not constrict or dilate cerebral pial arterioles. 15, 16 Current and previous studies thus each indicate that although propofol decreases CBF, it does not do so by constricting the pial microvasculature. À 4 mol/L dilated pial arterioles and venules. Intralipid had no effect on pial vessels. ILA indicates intralipid effects on large pial arterioles; ILV, intralipid effects on large pial venules; ISA, intralipid effects on small pial arterioles; ISV, intralipid effects on small pial venules; PLA, propofol effects on large pial arterioles; PLV, propofol effects on large pial venules; PSA, propofol effects on small pial arterioles; PSV, propofol effects on small pial venules. *P<0.05 compared with other concentrations of propofol; wP<0.05 compared with corresponding intralipid.
The current study confirmed that propofol per se had no pharmacologically vasoactive effects on cerebral pial vessels.
Therapeutic plasma concentrations of propofol are 1.5 to 5 mg/mL, 20 and molecular weight of propofol is 178.27. Therefore, typical clinical plasma concentrations of propofol are 1 to 3 Â 10 À 5 mol/L. Propofol binds extensively to plasma proteins and its unbound fraction in arterial plasma is less than 4%. 21 Because free propofol can affect pial arteriolar and venular diameters, clinically relevant propofol concentration in this study would be 1.2 Â 10 À 6 mol/L or less. Even at much higher 
concentrations (ie, Z10
À 5 mol/L), propofol had no substantial effects on pial arterioles or venules. Propofol at clinically relevant concentrations thus seems unlikely to directly affect pial arterial or venous tone.
In the present study, propofol was applied from outside the cerebral blood vessels. It is possible that extravascularly applied propofol does not inhibit sympathetic nerve activity the way endovascular drug does is known to. 17 Furthermore, systemically administered propofol may decrease blood pressure and CMR. Compared with IV administration, topical application of drugs permits the investigation of pial arteriolar responses without the confounding systemic effects such as change in blood pressure, metabolic rate, sympathetic activity, etc. If propofol were administered from the luminal side, the effects on cerebral pial vessels could be different from the present results.
Propofol at high concentrations dilates bovine coronary artery rings. 22 Likewise, previous in vitro studies have shown that supraclinical concentrations of propofol reduce the contractile response of human cerebral pial microvessels, 16 guinea pig basilar arteries, 14 and dilate canine cerebral arteries. 15 As might be expected from these studies, we observed that propofol at 10 À 4 mol/L produced pial arteriolar dilation in vivo. Propofol-induced vasodilation has been attributed to activation of K ATP channels, 12 nitric oxide, 13 a vasodilator prostanoid, 13 and inhibition of sympathetic vasoconstrictor nerve activity. 17 Propofol might thus possess the potential of being a vasodilator for pial vessels; however, the effects were not elicited until doses exceeded the clinical range by two-to-three orders of magnitude.
Additives to propofol include soya bean oil 100 mg/mL, glycerol 22.5 mg/mL, egg phosphatide 12 mg/mL, and disodium edetate 55 mg. Intralipid with disodium edetate consists of the same concentrations of those constituents of the vehicle for propofol. Nakamura et al 15 proposed that soya bean oil and egg phosphatide might contribute to the vasodilation of cerebral vessels in vitro. Our study, though, indicates that intralipid alone does not dilate pial vessels even at extreme concentrations. It is thus quite unlikely that the vehicle for propofol causes clinically important pial vascular dilation.
We used pentobarbital as a baseline anesthetic. It is possible that the pentobarbital anesthetic had produced either burst suppression or an isoelectric EEG in which case the ability of the propofol to impact vessel diameter may have been limited. EEG was not monitored in the first and second study, because rabbits' heads were covered with cranial window and EEG electrodes could not be pasted. We performed in the third study to measure the EEG and the BIS in rabbits in which cranial window was not implanted. The BIS showed between 64 and 82. Although the BIS algorithm of humans may not be applicable to that of rabbits, the BIS could help to determine anesthetic depth in rabbits. 23 It is unlikely that the dose of pentobarbital used in the present study induced deep anesthesia. Pentobarbital anesthesia did not produce either burst suppression or an isoelectric EEG in this study.
Furthermore, pial vessels may have been so constricted by pentobarbital that they could not have reacted to superfusion with propofol. Nevertheless, pentobarbital anesthesia has been used in this type of experiments. 24, 25 We proved in the additional study that the pial vessels were not irreversibly fixed into a constricted state by pentobarbital and responded to topical application of phenylephrine and nitroglycerin. We also detected that pial arteriolar and venular responses to phenylephrine or nitroglycerin were comparable between the first and second trial. In addition, pial arteriolar and venular diameters returned to control values 40 minutes after the last application. We confirmed that stability of the preparation was preserved during the study period.
Topical application of propofol could cause anesthesia and the duration of anesthetic effect is unknown. To minimize anesthetic effects of propofol, the test solutions were always administered in increasing concentrations. Using this method, former application of propofol might cause no or little effects on the next measurements. However, compared with random manner, escalating manner could involve subjective validation and confirmation bias. This is a potential weakness of the study. Nevertheless, pial arteriolar and venular diameters were measured after the experiments by a blinded investigator who did not participate in the experimental procedures. This study design may minimize the involvement of subjective validation and confirmation bias.
In conclusion, although the largest concentration of propofol we tested caused slight pial vasodilation, propofol had no effect on cerebral pial arteriolar or venular tone at anything resembling clinical concentrations. 
